New cocktail of Liver-Directed chemo and immunotherapy targets deadly bile duct cancer
NCT ID NCT07646717
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests a combination of liver-directed chemotherapy (irinotecan liposome plus 5-FU/LV) with targeted therapy (lenvatinib) and immunotherapy (PD-1 inhibitors) as a first treatment for advanced intrahepatic cholangiocarcinoma, a rare and aggressive bile duct cancer. The study enrolls 30 adults with unresectable or metastatic disease. The goal is to see if this approach can shrink tumors and improve outcomes, while monitoring side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- irinotecan liposome, 5-FU/LV, lenvatinib, and PD-1 inhibitors
- What this could lead to
- If successful, this combination could offer a new first-line treatment option to shrink tumors and improve survival for people with advanced bile duct cancer.
- What could go wrong
- This is a small, early-phase trial with only 30 participants, so results may not apply to everyone. The combination therapy also carries risks of serious side effects from chemotherapy, targeted therapy, and immunotherapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INTRAHEPATIC CHOLANGIOCARCINOMA (ICC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, 300060, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Spirulina's secret protein may shield the liver during surgery
- New drug cocktail aims to outsmart untreatable bile duct cancer
- AI could spot liver cancer types and predict survival without needle biopsy
- New drug cocktails aim to stop bile duct cancer return after surgery
- Anti-Inflammatory drug may boost cancer therapy in bile duct cancer
- New pill targets gene flaws in hard-to-treat bile duct cancer